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Impacts of Polymorphisms in Genes Encoding Renal Disease-related Molecules on Progression to 
End-stage Renal Failure in Patients with IgA Nephropathy
Shuhei Kotaki (Department of Nephrology, Saitama Medical School, Moroyama, Iruma-gun, Saitama 350 -0495, 
Japan)
Background/Purpose: Polymorphisms found in genes encoding proinflammatory/profibrotic molecules have 
been demonstrated to be associated with several kinds of renal diseases. We investigated these polymorphisms in 
IgA nephropathy (IgAN) patients undergoing hemodialysis (HD) and their significance on progression to end- stage 
renal failure (ESRF). Methods: To evaluate the role of polymorphisms in genes described below, we analyzed the 
association of these polymorphisms with progression to ESRF in histologically-proven IgAN patients undergoing 
HD using Kaplan-Meier method. Employed genes are angiotensin- converting enzyme, angiotensinogen, monocyte 
chemoattractant protein-1, chemokine receptor (CCR5), transforming growth factor-β1, E-selectin (SELE), and 
L-selectin (SELL). Results: The duration between renal biopsy and ESRF (induction to HD) was significantly shorter 
in IgAN patients with T1402 allele at the SELE gene, G(-642) allele or T712 allele at the SELL gene than those 
without them. Any other polymorphisms were not significantly associated with progression to ESRF in this study. 
Conclusion: This work provides evidence that the T1402C polymorphism of the SELE gene, A(-642)G and C712T 
polymorphisms of the SELL gene are associated with rapid progression to ESRF in IgAN patients.
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素（angiotensin converting enzym（ACE））10 -12)， ア ン
ギオテンシノーゲン（angiotensinogen（AGT））12 -14)，
インターロイキン-1受容体拮抗蛋白（interleukin-1





















































PCR条件：バッファー組成（50 µl）；100 ng DNA，3 
mM MgCl2， 50 mM KCl，10 mM Tris -HCl pH8.4，0.1 
mg/ml geletin， 0.5 mM of dNTPs（dATP, dTTP, dCTP, 
dGTP）， 1 µMプライマー，1unit Taq polymerase 
（TAKARA SHUZO）
30サイクル； denaturation 94 oC 1分； annealing 58 oC 







PCR条件：バッファー組成（50 µl）；100 ng DNA，15 
mM MgCl2， 50 mM KCl，10 mM Tris-HCl pH8.4，0.1 
mg/ml geletin， 0.5 mM of dNTP （dATP, dTTP, dCTP, 
dGTP）， 1 µM プライマー，1unit Taq polymerase 
30サイクル； denaturation 90 oC 1分； annealing 68 oC 













PCR条件：バッファー組成（50 µl）；100 ng DNA，1.5 
mM MgCl2， 50 mM KCl，10 mM Tris-HCl pH8.4，0.1 
mg/ml geletin， 0.5 mM of dNTP （dATP, dTTP, dCTP, 
dGTP）， 1 µM プライマー，1unit Taq polymerase 
30サイクル； denaturation 94 oC 30秒； annealing 64 oC 








PCR条件：バッファー組成（50 µl）；100 ng DNA，1.5 
mM MgCl2， 50 mM KCl，10 mM Tris-HCl pH8.4，0.1 
Fig. 2. AGT M235T and the progression to ESRF in IgAN 
patients. a. Gel patterns of AGT M235T polymorphism. 
Lane 1 shows the homozygous Thr/Thr genotype and lane 
2 is heterozygous Met/Thr. b. Met/Thr vs. Thr/Thr. No 
significant difference was seen between these groups.
Fig. 1. ACE D/I and the progression to ESRF in IgAN 
patients. a. Gel patterns of ACE D/I polymorphism. Lane 1 
shows the homozygous DD genotype, lane 2 is homozygous II 
and lane 3 is heterozygous DI. b. DD＋DI vs. II. No significant 
difference was seen between these groups. c. DI＋II vs. DD. 
No significant difference was seen between these groups.
Fig. 3. AGT A(-20)C and the progression to ESRF in IgAN 
patients. a. Gel patterns of AGT A(-20)C polymorphism. Lane 
1 shows the homozygous CC genotype, lane 2 is homozygous 
AA and lane 3 is heterozygous AC. b. AA＋AC vs. CC. No 
significant difference was seen between these groups. c. AC＋
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mg/ml geletin， 0.5 mM of dNTP （dATP, dTTP, dCTP, 
dGTP）， 1 µM プライマー，1unit Taq polymerase 
40サイクル； denaturation 94 oC 1分； annealing 56 oC 








PCR条件：バッファー組成（50 µl）；100 ng DNA，1.5 
mM MgCl2， 50 mM KCl，10 mM Tris-HCl pH8.4，0.1 
mg/ml geletin， 0.5 mM of dNTP（dATP, dTTP, dCTP, 
dGTP）， 1 µM プライマー，1unit Taq polymerase 
40サイクル； denaturation 95 oC 1分； annealing 58 oC 








PCR条件：バッファー組成（50 µl）；100 ng DNA，1.5 
mM MgCl2， 50 mM KCl，10 mM Tris-HCl pH8.4，50 
ml/L formamide， 0.5 mM of dNTP（dATP, dTTP, dCTP, 
dGTP）， 1 µM プライマー，1unit Taq polymerase 
35サイクル； denaturation 94 oC 30秒； annealing 60 oC 





Fig. 4. MCP-1 G(-2518)A and the progression to ESRF 
in IgAN patients. a. Gel patterns of MCP-1 G(-2518)A 
polymorphism. Lane 1 shows the homozygous GG genotype, 
lane 2 is homozygous AA and lane 3 is heterozygous GA. b. 
GG＋GA vs. AA. No significant difference was seen between 
these groups. c. GA＋AA vs. GG. No significant difference 
was seen between these groups.
Fig. 5. CCR5 G59029A and the progression to ESRF in IgAN 
patients. a. Gel patterns of CCR5 G59029A polymorphism. 
Lane 1 shows the homozygous AA genotype, lane 2 is 
homozygous GG and lane 3 is heterozygous GA. b. GG＋
GA vs. AA. No significant difference was seen between these 













PCR条件：バッファー組成（50 µl）；100 ng DNA，1.5 
mM MgCl2， 50 mM KCl，10 mM Tris-HCl pH8.4，0.5 
mM of dNTP （dATP, dTTP, dCTP, dGTP）， 1 µM プラ
イマ （ーRVおよびFW（C1402）もしくはFW（T1402）），
1unit Taq polymerase 
25サイクル； denaturation 95 oC 30秒； annealing 62 oC 









PCR条件：バッファー組成（50 µl）；100 ng DNA，1.5 
mM MgCl2， 50 mM KCl，20 mM Tris-HCl pH8.4，0.1 
mg/ml geletin， 0.5 mM of dNTP （dATP, dTTP, dCTP, 
dGTP）， 1 µM プライマー，1unit Taq polymerase 
35サイクル； denaturation 94 oC 30秒； annealing 60 oC 









PCR条件：バッファー組成（50 µl）；100 ng DNA，1.5 
mM MgCl2， 50 mM KCl，10 mM Tris-HCl pH8.4，25 
ml/L formamide，0.5 mM of dNTP （dATP, dTTP, dCTP, 
Fig. 6. TGF-β1 C(-509)T and the progression to ESRF 
in IgAN patients. a. Gel patterns of TGF-β1 C(-509)T 
polymorphism. Lane 1 shows the homozygous CC genotype, 
lane 2 is homozygous TT and lane 3 is heterozygous CT. b. 
CC＋CT vs. TT. No significant difference was seen between 
these groups. c. CT＋TT vs. CC. No significant difference was 
seen between these groups.
Fig. 7. SELE C1402T and the progression to ESRF in IgAN 
patients. a. Gel patterns of SELE C1402T polymorphism. Lane 
1 shows the homozygous TT genotype, lane 2 is homozygous 
CC and lane 3 is heterozygous CT. b. CC＋CT vs. TT. No 
significant difference was seen between these groups. c. CT
＋TT vs. CC. The progression to ESRF in IgA patients with 
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dGTP）， 1 µM プライマ （ーRVおよびFW（A（－642））
もしくはFW（G（－642））），1unit Taq polymerase 
25サイクル； denaturation 95 oC 30秒； annealing 63 oC 










PCR条件：バッファー組成（50 µl）；100 ng DNA，1.5 
mM MgCl2， 50 mM KCl，10 mM Tris-HCl pH8.4，15 
ml/L formamide，0.5 mM of dNTP （dATP, dTTP, dCTP, 
dGTP）， 1 µM プライマ （ーRVおよびFW（C712）もし
くはFW（T712）），1unit Taq polymerase 
25サイクル； denaturation 95 oC 30秒； annealing 62 oC 

























Fig. 8. SELE A561C and the progression to ESRF in IgAN 
patients. a. Gel patterns of SELE A561C polymorphism. Lane 
1 shows the homozygous AA, and lane 2 is heterozygous AC. b. 
AC vs. AA. No significant difference was seen between these 
groups.
Fig. 9. SELL A(-642)G and the progression to ESRF in IgAN 
patients. a. Gel patterns of SELL A(-642)G polymorphism. 
Lane 1 shows the homozygous GG genotype, lane 2 is 
homozygous AA and lane 3 is heterozygous AG. b. AA＋AG 
vs. GG. No significant dif ference was seen between these 
groups. c. AG＋GG vs. AA. The progression to ESRF in 
IgA patients with G(-642) was significantly faster than those 











































Fig. 10. SELL C712T and the progression to ESRF in IgAN 
patients. a. Gel patterns of SELL C712T polymorphism. Lane 
1 shows the homozygous TT genotype, lane 2 is heterozygous 
CT and lane 3 is homozygous CC. b. CC＋CT vs. TT. No 
significant difference was seen between these groups. c. CT＋
TT vs. CC. The progression to ESRF in IgA patients with T712 
was significantly faster than those without T712. (p＜0.0349)
Table 1. Genotype distribution and allele frequency of the 
ACE gene
Table 2. Genotype distribution and allele frequency of the 
AGT gene








































































Table 4. Genotype distribution and allele frequency of the 
TGF-β1 gene
Table 5. Genotype distribution and allele frequency of the 
SELE gene
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